Editorial Board et al., 2026-09: Update narrowing the journal's review to statistical and design questions and dropping the ethics/IRB line of inquiry, while stating that no allegation of misconduct is made.
Those requests have been withdrawn. The question of ethical oversight is not pursued and forms no part of the ongoing review.
Editorial Board et al., 2026-09: Update narrowing the journal's review to statistical and design questions and dropping the ethics/IRB line of inquiry, while stating that no allegation of misconduct is made. C5. Important for balance: the update withdraws the documentation requests on IRB approval and source verification, states the Board draws 'no adverse inference from the non-production of any material', and confines the review to the construction of the composite outcome, timing of baseline assessment, dose-adverse-effect relationship, representativeness analysis, dose-stratified composition, and handling of participants without follow-up and of concurrent conventional therapy. It also states no final decision had been taken at that date. The retraction followed in October. Excerpt from the PubMed abstract of the notice. Study type: other.
